Charles River Laboratories has announced an "end-to-end" service offering of CRISPR/Cas9 genome engineering technology, including custom in vivo and in vitro genome editing.
Celgene has made a second investment in a machine learning and simulation platform for applications across drug discovery, clinical development, and commercialization.
UK based clinical research organization (CRO), Ergomed, has bought out the Czech PharmInvent as a ‘bolt on’ to its own pharmacovigilance subsidiary, PrimeVigilance.
Breckenridge Pharmaceutical has entered into a multi-product marketing agreement with development and manufacturing partner Gland Pharma Limited for seven injectable products.
Accinov has teamed up with Canadian clinical research organisation (CRO) Biodextris to provide a transatlantic biomanufacturing ‘plug and play’ service for biopharmaceuticals—with a particular expertise in vaccines.
CRF Health is investing in a new office location and workforce in Romania as it continues to expand its product and service portfolio.
Content Provided by Reading Scientific Services Ltd.
Sometimes it's the smallest details that have the biggest impact on pharmaceutical performance. That's certainly true when it comes down to the properties of particles and their impact on pharmaceutical performance. Subtle changes in particle size, shape and distribution can have a major impact on pharmaceutical solubility, stability and efficacy.
Content Provided by World Courier
Southeast Asia is a growing pharmaceutical market, with a population of 620 million. What opportunities are there for multinational companies to access this rich area?